News Focus
News Focus
Followers 79
Posts 31776
Boards Moderated 2
Alias Born 12/30/2004

Re: bbotcs post# 88607

Wednesday, 07/07/2021 11:51:30 AM

Wednesday, July 07, 2021 11:51:30 AM

Post# of 130119
BHVN: OT because I'm venting

I mentioned this stock last year, after hearing Jim Cramer sing the praises of its migraine drug Nurtec (he uses it). I have owned it twice, and didn't buy back when it went down (because its Alzheimer's candidate failed??--I'm not sure). In any event, it was apparent to anyone that Nurtec has blockbuster potential. Not too long ago, it received FDA approval for use as a preventive drug, not just for use when migraines occur.

Today, the stock was up $11 on news that the Q2 revs for Nurtec are expected to be approximately $92 million.

This company is working on other neurological drug candidates.

If it drifts back to $100 or below, I'm buying. And here is a little extraneous info on migraine treatments. Maybe 30 years ago, the pharma industry introduced triptans for treating migraines, but they are contraindicated for people with heart conditions. Before tripans were introduced, a VERY inexpensive generic drug was available on the U.S. to treat migraines--Caffregot. It was a combination of ergot (a fungus that grows on wheat) and caffeine. It was 100 effective in relieving migraine pain when taken at the onset of migraine; if the migraine had progressed, it didn't work. Regardless, it was a very cheap drug that helped millions of migraine sufferers. The evil Pharma industry took it off the market when they introduced the tripans, which were not cheap, and unavailable for financially challenged people and too expensive for people without drug insurance. EVIL.

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today